Shea Michael L, Conti C Richard, Arora Rohit R
Division of Cardiovascular Disease and Hypertension, Department of Medicine, Robert Wood Johnson Medical School-UMDNJ, New Brunswick, New Jersey 08903-0019, USA.
Clin Cardiol. 2005 Mar;28(3):115-8. doi: 10.1002/clc.4960280304.
The development of advanced revascularization techniques has resulted in the growth of a subset of patients with coronary artery disease who are nonrevascularizable and are considered to have refractory angina. Enhanced external counterpulsation (EECP) has been developed for the management of these patients with chronic, refractory disease. Evidence has shown that through improvement of vascular endothelial function and recruitment of collateral vessels, EECP provides many clinical benefits. These patients experience sustained decreases in angina, improvement in exercise time, improved myocardial perfusion, and enhanced quality of life. Furthermore, EECP appears to be safe and effective in the treatment of angina in patients with impaired systolic function and has similar potential in patients with congestive heart failure.
先进的血管重建技术的发展导致了一部分冠状动脉疾病患者的增加，这些患者无法进行血管重建，被认为患有顽固性心绞痛。增强型体外反搏（EECP）已被开发用于治疗这些患有慢性顽固性疾病的患者。证据表明，通过改善血管内皮功能和募集侧支血管，EECP带来了许多临床益处。这些患者的心绞痛持续减轻，运动时间改善，心肌灌注提高，生活质量增强。此外，EECP在治疗收缩功能受损患者的心绞痛方面似乎是安全有效的，并且在充血性心力衰竭患者中具有类似的潜力。
